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lObjectives: To explore the validity and reliability of a disease-specific
health-related quality-of-life questionnaire—the Schizophrenia Qual-
ity of Life Scale Revision 4 (SQLS-R4)—in patients with schizophrenia in
Malaysia. Methods: A total of 222 outpatients with schizophrenia re-
ceiving treatment at the Universiti Kebangsaan Malaysia Medical Cen-
tre completed the SQLS-R4 in either the Malay or the English language.
A generic self-report health-related quality-of-life measure—the Euro-
QoL group EuroQol five-dimensional questionnaire—and a measure of
symptom severity—the Clinical Global Impression-Schizophrenia
scale—were also administered to assess validity. Results: Good inter-
nal consistency reliability was found for both the psychosocial and
vitality domains (Cronbach’s   0.95 and 0.85, respectively). Most
items were also significantly correlated with their own scale score (rsthe SQLS-R4 “vitality” domain and the EuroQol five-dimensional ques- O
m
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cy, U
al So
oi:10.1016/j.vhri.2012.03.006ionnaire “usual activities” domain (rs  0.44) and a large correlation
etween the SQLS-R4 “psychosocial” domain and the EuroQol five-di-
ensional questionnaire “anxiety/depression” domain (rs  0.44–
.57). Most of the symptom dimensions of the Clinical Global Impres-
ion-Schizophrenia scale were also moderately correlated with the
QLS-R4 subscale scores. Conclusions: The SQLS-R4 is a valid and re-
iable health-related quality-of-life instrument for use in minimally ill
atients with schizophrenia in Malaysia, but some of the itemsmay be
edundant and irrelevant. Validation of SQLS-R4 in different types of
atients and various levels of illness severity is required to further
erify its application.
eywords: health-related quality of life, reliability, schizophrenia, va-
idity.ranging from 0.29 to 0.74). There was a moderate correlation between Copyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
For the past two decades, health-related quality of life (HRQOL)
has increasingly become an important outcome measure in clini-
cal trials, health services research, patient management, and re-
source allocation [1]. Similarly, the development of new antipsy-
chotic medications has resulted in HRQOL being an essential
measure of treatment success in schizophrenia [2]. Internationally
defined as the patient’s self-reported health and ability to function
physically,mentally, and socially, HRQOLdescribed an array of life
dimensions affected by disease and treatment interventions [3].
Thus, it is a significant outcome in schizophrenia, a debilitating
psychiatric disorder that causes profound disruptions in many
areas of patients’ life functioning [4].
Many instruments have been developed to measure HRQOL,
but there is no consensus on the most appropriate scale for mea-
suring HRQOL in schizophrenia [5]. The instrument of choice for
HRQOL measurement depends on the assessment purposes [6].
Generic instruments designed to be applicable across all diseases
or conditions are likely to be useful in comparing different group of
Conflicts of interest: The authors have indicated that they hav
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212-1099/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.patients, while disease-specific measures have more potential in
detecting treatment effects [7]. Schizophrenia-specific question-
naires such as the Heinrichs-Carpenter Quality of Life Scale, the
Drug Attitude Inventory, and the Subjective Well-being under
Neuroleptics have been used to evaluate the effectiveness of anti-
psychotic medications on HRQOL. The predominantly used scale
is the Heinrichs-Carpenter Quality of Life Scale [7]. Although the
Heinrichs-Carpenter Quality of Life Scale has historical values, it is
an observer-rated instrument primarily designed to address neg-
ative symptoms in schizophrenia [6].
One of the essential features of a schizophrenia-specific
HRQOL instrument includes incorporation of life domains
highly relevant to individuals with schizophrenia [8]. One such
measure is the Schizophrenia Quality of Life Scale by Wilkinson
et al. [9], a brief self-report scale that has been translated into 52
languages including the Malay language through standardized
procedures and validated in several East Asian countries such
as Japan, Korea, and Taiwan [10–12]. Currently available in its
ost recent revised form, the Schizophrenia Quality of Life
cale Revision 4 (SQLS-R4) comprises items that concern those
conflicts of interest with regard to the content of this article.
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83V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 8 2 – 8 6suffering from schizophrenia and is thus of potential use in
clinical trials and evaluation of clinical interventions such as
drug treatments [10].
Patients with schizophrenia inMalaysia have been living in the
community since community-based psychiatric services were es-
tablished in numerous hospitals [13]. Although several studies
ave been conducted to examine their life qualities, none has re-
orted the use of the SQLS-R4. The effect of antipsychotics in pa-
ients with schizophrenia is substantial because of not only their
otential to alleviate symptoms but also the impact of side effects
n patients’ functioning and well-being [14]. Partly designed to
assess the effect of antipsychotic medications on HRQOL, the
SQLS-R4 has prior evidence of excellent psychometric properties
[15], thus rendering it a potential tool for determining HRQOL
among patients with schizophrenia in Malaysia, primarily man-
aged by pharmacological treatment. The objective of this study
therefore was to evaluate the validity and reliability of the
SQLS-R4 as an outcome measure of HRQOL among patients with
schizophrenia in Malaysia.
Methods
Subjects
A convenience sample of 222 outpatients with schizophrenia at-
tending the Psychiatry Clinic at Universiti Kebangsaan Malaysia
Medical Centre was enrolled in the study. Inclusion criteria for
subject selectionwere 1) a diagnosis of schizophrenia according to
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion, American Psychiatric Association 1994, 2) age between 18 and
65 years, 3) clinically stable (not acutely ill or has not been recently
hospitalized at least for the past 3months), 4) has fair understand-
ing of the illness, 5) understandsMalay or English language, and 6)
provided consent to participate in the study. Patients who were
pregnant or those who had an associated diagnosis of mental re-
tardation, organic brain diseases, or substance abuse were ex-
cluded.
Measure
The SQLS-R4 was developed by Wilkinson et al. [9] for the mea-
surement of HRQOL in people with schizophrenia. It comprises 33
items incorporated in two domains: psychosocial feelings (22
items) and cognition and vitality (11 items). All except four items
are scored on a five-point Likert-type scale (0  never, 1  rarely,
 sometimes, 3  often, 4  always), with the exceptional four
tems being reverse coded (0  always, 1  often, 2  sometimes,
 rarely, 4 never). Individual domain and total scores are stan-
ardized by scoring algorithm to a 0 to 100 scale, with higher
cores indicating comparatively lower quality of life. Its factor
tructure and internal reliability have been verified in schizo-
hrenic patients in the Netherlands and further replicated in a
roup of patients with schizophrenia in the United Kingdom and
aiwan [12,15].
The EuroQol Group EuroQol five-dimensional (EQ-5D) ques-
ionnaire is a simple generic instrument that generates a health
rofile and preference-based index scores of HRQOL [16]. The
rst part is a descriptive system (EQ-5D self-classifier) that fa-
ilitates individuals to categorize their health condition in five
imensions, mobility, self-care, usual activities, pain/discom-
ort, and anxiety/depression, with each dimension divided into
hree levels of severity ranging from 1 (no problem) to 3 (many
roblems). The second section consists of a vertical visual ana-
ogue scale (VAS), with end points of 0 and 100 indicating
worst” and “best” imaginable health state, respectively. The
hird section is the EQ-index, which represents a series of soci-
tal preferential values for the full set of 243 health states, withhe states of perfect health and death usually being assigned
alues of 1 and 0, respectively. Only the EQ-5D self-classifier and
he EQ-VAS were used for the present study.
The Clinical Global Impression-Schizophrenia (CGI-SCH) scale
s a simple and brief scale adapted from theClinical Global Impres-
ion scale that has a widespread application in rating the overall
everity of anymental disorder [17]. The CGI-SCH scale specifically
easures the severity of illness and degree of change in schizo-
hrenia in four symptom dimensions, positive, negative, depres-
ive, and cognitive, as well as overall severity rated on a seven-
oint scale ranging from 1 (no illness) to 7 (most severe possible)
18]. For the purpose of the present study, only the CGI-SCH Sever-
ty of Illness scale was used.
Procedure
Patients’ case notes were screened to identify eligible subjects for
the study. Patients who fulfilled all the inclusion criteria were in-
vited to participate and given an explanation about the study. Pa-
tients who provided written informed consent were then asked to
complete the self-administered SQLS-R4, the EQ-5D self classifier,
and EQ-VAS, which were available in two languages: the Malay
language and the English version for Malaysia. Demographic and
clinical data were compiled by case-note review and patients’ in-
terviews. Patients’ clinical status was assessed via the CGI-SCH
Severity of Illness scale by the attending clinician. The research
protocol of the study was approved by the Medical Research and
Ethics Committee of the Universiti Kebangsaan Malaysia Medical
Centre.
Statistical analysis
Patient characteristics were presented by using descriptive sta-
tistics. The internal consistency of the SQLS-R4 was determined
by item to total correlations and Cronbach’s alpha coefficients.
It was hypothesized that the EQ-5D “anxiety/depression” do-
main would be addressing issues related to those of the SQLS-R4
“psychosocial” domain and the “cognition/vitality” domain
would be associated with the “usual activities” domain. Corre-
lations of items with their scale totals of at least 0.40 and a value
of Cronbach’s alpha between 0.70 and 0.90 are highly suggested
for a robust scale [19]. The construct validity and clinical valid-
ity was established by comparing scores of the SQLS-R4 sub-
scales with those of the EQ-5D self-classifier and the CGI-SCH
scale, respectively, by means of Spearman’s rank correlations.
Correlation was considered large for |rs| 0.5, moderate for 0.3
|rs|  0.5, and small for 0.1  |rs|  0.3 [20]. For all analyses, the
level of statistical significance was defined as alpha less than
0.05. The statistical analyses were performed by using the Sta-
tistical Package for the Social Sciences, version 16.0 (SPSS, Inc.,
Chicago, IL).
Results
Of the 222 subjects, 192 (86.5%) completed the SQLS-R4 in Malay
and 30 (13.5%) completed the SQLS-R4 in English. The subjects
comprised nearly equal number ofmen andwomenwithminimal
symptoms severity. The ethnic group composition of the study
subjects was reflective of a Malaysian population, with the major-
ity of the patients being Malay followed by Chinese and Indian.
Most other background characteristics of the subjects were also
comparable with those of schizophrenic outpatients found in
other catchment area inMalaysia [13,21]. Table 1 shows the demo-
graphic characteristics of the subjects. The baseline scores of
SQLS-R4 subscales and the distribution of the scores are shown in
Table 2. A broad range of scores was observed for both the psycho-
social and vitality subscales. For both the subscales, floor effects
(the percentage of patients acquiring the lowest score) and ceiling
84 V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 8 2 – 8 6effects (the proportion of patients achieving the highest score)
were minimal.
Correlations of items with their respective subscale (corrected
to omit the item being correlated) and Cronbach’s alpha coeffi-
cients of each subscale were computed to determine the internal
Table 1 – Characteristics of study subjects (n = 222).
Variables
Age (y), mean  SD 37.73  10.13
Sex, n (%)
Men 110 (49.5)
Women 112 (50.5)
Ethnicity, n (%)
Malay 117 (52.7)
Chinese 78 (35.1)
Indian 26 (11.7)
Others 1 (0.5)
Marital status, n (%)
Single 154 (69.4)
Married 68 (30.6)
Education background, n (%)
Primary 15 (6.8)
Secondary 157 (70.7)
Tertiary 50 (22.5)
Living arrangement, n (%)
Family 207 (93.2)
Independent 15 (6.8)
Employment status, n (%)
Employed 113 (50.9)
Unemployed 109 (49.1)
Age at onset (y), mean  SD 26.24 (7.78)
Duration of illness (y), mean  SD 11.42  8.02
CGI-SCH scale score*
Median (IQR)
Overall symptoms 2.0 (2.0)
Positive symptoms 1.0 (1.0)
Negative symptoms 2.0 (1.0)
Depressives symptoms 1.0 (1.0)
Cognitive symptoms 1.5 (1.0)
IQR, interquartile range.
* Clinical Global Impression-Schizophrenia Severity of Illness scale
rated on a seven-point scale with 1  normal and 7  extremely
ill.
Table 2 – Distribution of SQLS-R4 subscale scores.
Scale
Psychosocial Vitality
n 220 221
Mean 31.22 36.00
SD 21.23 18.23
Median 30.00 36.54
Range of scores* 0–93.75 0–82.69
% scoring minimum 3.6 0.9
% scoring maximum 0 0
25th percentile 12.50 23.08
50th percentile 30.00 36.54
75th percentile 46.25 48.08
SQLS-R4, Schizophrenia Quality of Life Scale Revision 4.
* Score of each scale ranges from 0 (best possible health) to 100(worst possible health).consistency of the psychosocial and vitality subscales of the
SQLS-R4 (Table 3). For most items, corrected item to total correla-
tions were satisfactory, ranging from 0.51 to 0.74 in the psychoso-
cial domain and 0.45 to 0.70 in the vitality domain, above the 0.40
criterion for item-internal consistency. Nonetheless, three items
from the vitality subscale had correlations less than or equal to
Table 3 – Correlation coefficients of corrected items to
total scores and internal reliability of SQLS-R4 subscales
(Cronbach’s alpha).
Scale and items Item to total
correlation
Cronbach’s
alpha
Psychosocial
Item 3 (Worry about future) 0.62 0.95
Item 4 (Feel lonely) 0.62
Item 5 (Feel hopeless) 0.65
Item 6 (Feel panicky) 0.62
Item 8 (Take things people
say the wrong way)
0.57
Item 10 (Difficult to mix with
people)
0.67
Item 11 (Feel down) 0.70
Item 13 (Feel very mixed up) 0.70
Item 15 (Feelings go up and
down)
0.72
Item 16 (Concerned won’t get
better)
0.67
Item 17 (Worry about things) 0.74
Item 18 (Feel people avoid me) 0.67
Item 19 (Get upset thinking
about the past)
0.70
Item 21 (Feel cut off from the
world)
0.72
Item 22 (Feel uncomfortable
with people)
0.70
Item 24 (Has upsetting
thoughts)
0.69
Item 25 (Has suicidal thoughts) 0.51
Item 27 (Feel depressed) 0.62
Item 29 (Feel restless) 0.70
Item 30 (Concerned about
social life)
0.68
Cognition and vitality 0.85
Item 1 (Lack energy to do
things)
0.57
Item 2 (Can’t be bothered to
do things)
0.52
Item 7 (Able to carry out daily
activities)
0.34
Item 9 (Find hard to
concentrate)
0.64
Item 12 (Feel I can cope) 0.40
Item 14 (Sleep well) 0.29
Item 20 (Trouble remembering
things)
0.56
Item 23 (Has trouble thinking
clearly)
0.55
Item 26 (Feel happy) 0.47
Item 28 (Feel drowsy) 0.45
Item 31 (Feel tired) 0.62
Item 32 (Feel physically weak) 0.70
Item 33 (Feel like not leading a
normal life)
0.58
Note. For all correlations, P  0.01.
SQLS-R4, Schizophrenia Quality of Life Scale Revision 4.0.40—item 7: able to carry out daily activities (rs  0.34), item 12:
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ronbach’s alpha values for psychosocial and vitality subscales
ere 0.95 and 0.85, respectively, beyond the 0.70 standard for ac-
eptable instrument internal reliability. The deletion of any of the
3 items also did not improve the Cronbach’s alpha values for both
omains.
Construct validity of the SQLS-R4 scale was explored bymea-
uring its associations with the EQ-5D questionnaire and the
GI-SCH scale (Table 4). Correlations between the SQLS-R4 sub-
cales and domains of the EQ-5D questionnaire ranged from
.07 to 0.57. The SQLS-R4 “psychosocial” domain score was sig-
ificantly correlated with most of the EQ-5D questionnaire do-
ains except the “mobility” and “self-care” domain scores. As
nticipated, a large correlation was found between the SQLS-R4
psychosocial” dimension score and the EQ-5D questionnaire
anxiety/depression” domain score (rs  0.57). The SQLS-R4 “vi-
ality” dimension scores had moderate correlations with the
Q-5D questionnaire “usual activities” (rs  0.44) and “pain/dis-
comfort” domain scores (rs  0.42) and were also strongly cor-
elated with the “anxiety/depression” scores (rs  0.51). Signif-
icant correlations were also found between the EQ-VAS scores
and both the SQLS-R4 subscale scores (rs  0.37 and 0.43 for
sychosocial and vitality domain, respectively). Most of the CGI-
CH scale symptom scores except for the negative symptom
cores were alsomodestly correlated with subscale scores of the
QLS-R4 (rs  0.33–0.39 and rs  0.36– 0.44 for psychosocial and
vitality domain, respectively).
Discussion
Overall, the psychometric characteristics of the SQLS-R4 scale
were good. Assessment of the internal consistency revealed sig-
nificantly high correlations of items with their scale total except
for three items. Similar findings were also found in the validation
of the SQLS-R4 among patients with schizophrenia in Japan [10]
nd Taiwan [12].
As suggested by Kuo et al. [12], these results may be indica-
ive of those items being interpreted differently from the vitality
Table 4 – Correlations between the SQLS-R4, the EQ-5D
questionnaire, and the CGI-SCH scale.
SQLS-R4
Psychosocial Vitality
EQ-5D questionnaire
Mobility 0.07 0.17*
Self-care 0.12 0.09
Usual activities 0.31† 0.44†
Pain/discomfort 0.32† 0.42†
Anxiety/depression 0.57† 0.51†
VAS 0.37† 0.43†
CGI-SCH Scale
Overall symptoms 0.33† 0.44†
Positive symptoms 0.39† 0.38†
Negative symptoms 0.19† 0.27†
Depressive symptoms 0.37† 0.36†
Cognitive symptoms 0.37† 0.39†
Note. Higher scores on the SQLS-R4 indicate worst condition, while
higher scores on the EQ-VAS indicate a better condition.
CGI-SCH, Clinical Global Impression-Schizophrenia Severity of Ill-
ness scale; EQ-5D questionnaire, EuroQoL five-dimensional ques-
tionnaire; SQLS-R4, Schizophrenia Quality of Life Scale Revision 4;
VAS, visual analogue scale.
* P  0.05 by Spearman’s rank correlation.
† P  0.01.onstruct in the Asian customs. Alternatively, because of thestudy design, the study included patients with minimal severity
of symptoms and so those items with low item-total correla-
tions may not be relevant to clinically stable patients. Patients
in the Taiwan and Japan study also comprised psychologically
stable patients, but sample size for both studies was relatively
smaller.
The internal consistency of SQLS-R4 as reflected by Cronbach’s
alpha was also as high as those found in the Taiwan [12] and UK
study [15]. A Cronbach’s alpha of greater than 0.90 implies redun-
dancy where several items in the psychosocial domain asked sim-
ilar issues [19].
A prior study had utilized the short form 36 health survey to
validate the SQLS-R4 [12]. Here, the EQ-5D questionnaire was used
instead because it is a widely used and brief HRQOL measure.
Moreover, it had been shown to have acceptable discriminative
and construct validity in patients with schizophrenia [3]. Strong
correlations between the EQ-5D questionnaire “anxiety/depres-
sion” dimension and the SQLS-R4 domains demonstrate that the
EQ-5D questionnaire indeed assessed the same concepts, and
state of anxiety or depression also affects patient’s vitality. Alter-
natively, no significant correlation found between the EQ-5Dques-
tionnaire “mobility” and “self-care” domains and the SQLS-R4 “vi-
tality” domain may be because subjects in the present study were
outpatients who haveminimal severity and no apparent difficulty
to move or care for themselves.
The negative correlation between scores on the SQLS-R4 sub-
scales and the EQ-VAS also confirmed the expected direction of
association between the SQLS-R4 and the EQ-5D questionnaire or
convergent validity of the SQLS-R4. Higher scores on the SQLS-R4
show a worse condition, whereas higher scores on the EQ-VAS
indicate a better condition [12].
With the exception of negative symptoms, all the symptom
scores of the CGI-SCH scale were also modestly correlated with
the overall and the SQLS-R4 subscales scores. Findings regard-
ing the correlations between psychopathology and HRQOL had
been ambivalent, but negative symptoms had been commonly
associated with reduced quality of life among schizophrenia
patients [22]. Patients with predominantly negative symptoms
who normally display characteristics of anhedonia (social with-
drawal) are rather uncommunicative and are thus an obvious
obstacle during recruitment into the study, resulting in
them being possibly inadvertently excluded from the present
study.
The present study was limited in terms of study subjects be-
cause the sample consisted mainly of clinically stable chronic pa-
tients with minimal severity of illness. Therefore, further investi-
gation that includes different types of patients and patients with
various degree of symptom severity is required to verify further
the reliability of the SQLS-R4 and its application as an HRQOL out-
come measure.
Conclusions
The study provides initial evidence for the validity and reliabil-
ity of the SQLS-R4 in patients with schizophrenia in Malaysia.
the SQLS-R4 displayed good psychometric properties and has
potential use as a self-report schizophrenia-specific HRQOL in-
strument. However, some of the items in the scale may be re-
dundant and inappropriate for patients with minimal severity
of symptoms.
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